Table 3.
Effect of imatinib on fetal mortality rate at the 20th day of gestation.
| Groups | No. of sacrificed uteri | Developing fetuses |
Pre-implantation loss | Post-implantation loss | |||||
|---|---|---|---|---|---|---|---|---|---|
| Number |
No. of living fetuses | Stillbirths % | Resorbed % | Total mortality % | |||||
| Total number | No. of fetuses per litter | No. % |
No. % |
No. % |
No. % |
||||
| Control | 8 | 57 | 7.12 | 57 100% |
– – |
– – |
– – |
0% | 0% |
| Imatinib low dose (6th–13th) | 6 | 41 | 5.12 | 41 100% |
– – |
– – |
– – |
0% | 0% |
| Imatinib low dose (13th–19th) | 8 | 68 | 8.5 | 43 63.23% |
1 1.47% |
24 35.29% |
25 36.76% |
11.69% | 36.76% |
| Imatinib high dose (6th–13th) | 5 | 39 | 4.12 | 27 81.81% |
– – |
6 18.18% |
6 18.18% |
29.09% | 30.77% |
| Imatinib high dose (13th–19th) | 6 | 42 | 5.25 | 15 35.71% |
11 26.19% |
16 38.09% |
27 64.28% |
17.65% | 64.29% |